Anteris Technologies Global Corp (AVR) - Total Assets

Latest as of September 2025: AU$19.07 Million AUD ≈ $13.50 Million USD

Based on the latest financial reports, Anteris Technologies Global Corp (AVR) holds total assets worth AU$19.07 Million AUD (≈ $13.50 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See debt-free asset ratio of Anteris Technologies Global Corp to measure how much of total assets are equity-financed.

Anteris Technologies Global Corp - Total Assets Trend (2003–2024)

This chart illustrates how Anteris Technologies Global Corp's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of Anteris Technologies Global Corp to evaluate the quality of earnings relative to operating cash generation.

Anteris Technologies Global Corp - Asset Composition Analysis

Current Asset Composition (December 2024)

Anteris Technologies Global Corp's total assets of AU$19.07 Million consist of 92.5% current assets and 7.5% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 87.3%
Accounts Receivable AU$2.25 Million 1.7%
Inventory AU$828.85K 0.6%
Property, Plant & Equipment AU$0.00 0.0%
Intangible Assets AU$305.37K 0.2%
Goodwill AU$0.00 0.0%

Asset Composition Trend (2003–2024)

This chart illustrates how Anteris Technologies Global Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Anteris Technologies Global Corp stock valuation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Anteris Technologies Global Corp's current assets represent 92.5% of total assets in 2024, an increase from 73.4% in 2003.
  • Cash Position: Cash and equivalents constituted 87.3% of total assets in 2024, up from 73.4% in 2003.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 22.0% in 2003.
  • Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.

Anteris Technologies Global Corp Competitors by Total Assets

Key competitors of Anteris Technologies Global Corp based on total assets are shown below.

Company Country Total Assets
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
Germany €2.83 Billion
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
China CN¥16.89 Billion
Novocure Ltd
NASDAQ:NVCR
USA $787.93 Million
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
China CN¥2.00 Billion
Jafron Biomedical Co Ltd
SHE:300529
China CN¥5.52 Billion
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236
China CN¥3.54 Billion
Tellgen Corp
SHE:300642
China CN¥2.01 Billion
EBR Systems Inc
AU:EBR
Australia AU$97.29 Million

Anteris Technologies Global Corp - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.84 0.96 1.03
Quick Ratio 0.80 0.92 0.94
Cash Ratio 0.00 0.00 0.00
Working Capital AU$-2.21 Million AU$-784.36K AU$253.37K

Anteris Technologies Global Corp - Advanced Valuation Insights

This section examines the relationship between Anteris Technologies Global Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 148.85
Latest Market Cap to Assets Ratio 6.50
Asset Growth Rate (YoY) 185.3%
Total Assets AU$130.39 Million
Market Capitalization $848.00 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Anteris Technologies Global Corp's assets at a significant premium (6.50x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Anteris Technologies Global Corp's assets grew by 185.3% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Anteris Technologies Global Corp (2003–2024)

The table below shows the annual total assets of Anteris Technologies Global Corp from 2003 to 2024.

Year Total Assets Change
2024-12-31 AU$130.39 Million
≈ $92.26 Million
+185.30%
2023-12-31 AU$45.70 Million
≈ $32.34 Million
+94.64%
2022-12-31 AU$23.48 Million
≈ $16.61 Million
-20.36%
2021-12-31 AU$29.48 Million
≈ $20.86 Million
+133.03%
2020-12-31 AU$12.65 Million
≈ $8.95 Million
-51.35%
2019-12-31 AU$26.00 Million
≈ $18.40 Million
-18.38%
2018-12-31 AU$31.86 Million
≈ $22.54 Million
+12.30%
2017-12-31 AU$28.37 Million
≈ $20.07 Million
-0.73%
2016-12-31 AU$28.58 Million
≈ $20.22 Million
+6.71%
2015-12-31 AU$26.78 Million
≈ $18.95 Million
-35.10%
2014-12-31 AU$41.26 Million
≈ $29.19 Million
+3.77%
2013-12-31 AU$39.76 Million
≈ $28.13 Million
+140.05%
2012-12-31 AU$16.56 Million
≈ $11.72 Million
+47.92%
2011-12-31 AU$11.20 Million
≈ $7.92 Million
-24.07%
2010-12-31 AU$14.75 Million
≈ $10.44 Million
+954.79%
2009-12-31 AU$1.40 Million
≈ $989.32K
+7.45%
2008-12-31 AU$1.30 Million
≈ $920.69K
-16.80%
2007-12-31 AU$1.56 Million
≈ $1.11 Million
-39.47%
2006-12-31 AU$2.58 Million
≈ $1.83 Million
-34.15%
2005-12-31 AU$3.92 Million
≈ $2.78 Million
+2.53%
2004-12-31 AU$3.83 Million
≈ $2.71 Million
-24.49%
2003-12-31 AU$5.07 Million
≈ $3.59 Million
--

About Anteris Technologies Global Corp

AU:AVR Australia Medical Devices
Market Cap
$925.12 Million
AU$1.31 Billion AUD
Market Cap Rank
#9815 Global
#246 in Australia
Share Price
AU$13.50
Change (1 day)
+2.66%
52-Week Range
AU$4.69 - AU$13.80
All Time High
AU$83.50
About

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calci… Read more